SOLICITATION NOTICE
B -- Obtain Individual Data on Cancer Detection from the European Randomized Study of Screening for Prostate Cancer Trial
- Notice Date
- 8/16/2011
- Notice Type
- Presolicitation
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110158-LG
- Archive Date
- 9/15/2011
- Point of Contact
- Laura Glockner, Phone: 3014968607
- E-Mail Address
-
laura.glockner@nih.gov
(laura.glockner@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6074, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Control and Population Sciences (DCCPS) plans to procure on a sole source basis data from the European Randomized Study of Screening for Prostate Cancer from Erasmus Medical Center, Department of Urology, DR. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541990 and the business size standard is $7.0 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. In 2009, two important papers published interim results on the efficacy of Protein-Specific Antigen (PSA) Screening for Prostate Cancer from the two largest, cooperative, randomized, controlled trials in the world - one in the United States and the other in Europe. While the European Randomized Study of Screening for Prostate Cancer (ERSPC) indicate a clear benefit of screening the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer, the Screening Trial in the US showed no benefit. Although the trial results are apparently in conflict, there are many differences in their designs and implementation that makes results comparison difficult. As a consequence, the important question on the benefit of screening prostate cancer with PSA remains answered. Modeling provides a unique opportunity to clarify the message on screening benefit contained in the two trials. Understanding the likely benefit of PSA screening on prostate cancer mortality is critical for the general public and the clinical community as a whole; and has high public health significance, since clinicians and men face the decision of PSA screening for prostate cancer each day. Obtaining individual and detailed data from each of the trials is crucial to inform the models and to translate the results of the trials. Resolving the current controversies has the potential to have significant impact in the practice of PSA Screening in the United States. The Cancer Intervention and Surveillance Modeling Network (CISNET) is a consortium of NCI funded modelers whose purpose is to utilize simulation and other modeling techniques to understand the impact of cancer control interventions (i.e. screening, treatment, prevention) on national trends in cancer rates, and to inform national/regional/local decisions on the most efficient utilization of existing and emerging technologies and strategies for the control of cancer. The CISNET prostate group is engaged in a collaborative effort with other leading research institutions in the study of Prostate Cancer to use their models in the analysis of the trials results in order to investigate differences on the efficacy of PSA screening for prostate cancer. More specifically, the CISNET group is interested in estimating a "true" benefit of PSA screening that is independent of the trial implementation and design. The CISNET group has been conducting analysis using published results from the trials; however, the use of individual data has proved to be crucial for the continuation of this project. The purpose of this requirement is to obtain data from the European Randomized Study of Screening for Prostate Cancer (ERSPC), a large and highly-confidential dataset involving a multi-center (7 European countries), to inform the CISNET models and to address the current controversies surrounding the benefits of PSA Screening. The European Randomized study of Screening for Prostate Cancer (ERSPC) was established more than 12 years ago and is the largest ever randomized study on screening for prostate cancer. The ERSPC trial is an extremely valuable dataset. This dataset is unique due to the magnitude of patients' enrolled (approximately 182,000 men from 7 European countries) and the long follow-up time, high compliance and lower contamination of the control group. The Department of Urology, Erasmus Medical Center, is the holder of the ERSPC data; it coordinates and disseminates information for data requests from other European countries, and is also the world leader in the development of micro-simulation models to investigate the effect of screening strategies on population cancer trends. It is part of the NCI CISNET prostate modeling group, and it has a deep understanding about how data from randomized screening trials can be used to estimate screening efficacy and calibrate models. Accordingly, it is uniquely qualified to provide individual data on cancer detection from both arms of the ERSPC trial (intervention and control arm) under this proposed procurement. This notice is not a request for a competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on August 31, 2011. For further information, please contact Laura Glockner, Contract Specialist via electronic mail at laura.glockner@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-110158-LG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110158-LG/listing.html)
- Record
- SN02536340-W 20110818/110816235828-d7938061a1302a75a3b351e3ee8b7a63 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |